Findings

What do systematic reviews say?

1,497 questions · 1,590 findings · 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certainty Download CSV

No studies found 281 · 17.7%GRADE not reported 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Intervention not reported

Overall fatigue · people who are undergoing active treatment for cancer

1 finding from 1 review

Exercise interventions on health‐related quality of life for people with cancer during active treatment 2012 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 1721 participants
Very low

Intervention not reported

Overall physical function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer

1 finding from 1 review

Exercise interventions on health‐related quality of life for people with cancer during active treatment 2012 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 540 participants
Very low

Primary Groin Radiotherapy vs Primary Groin Surgery

Groin recurrence · patients with Early Vulvar Cancer

Primary Groin Radiotherapy showed no clear difference in groin recurrence compared with primary Groin Surgery (low certainty).

1 finding from 1 review

Primary groin irradiation versus primary groin surgery for early vulvar cancer 2011 · Cochrane Headline outcomes only
RR 10.21 [0.59, 175.78]
1 study · 52 participants
Low

Primary Groin Radiotherapy vs Primary Groin Surgery

Disease specific mortality · patients with Early Vulvar Cancer

Primary Groin Radiotherapy showed no clear difference in disease specific mortality compared with primary Groin Surgery (low certainty).

1 finding from 1 review

Primary groin irradiation versus primary groin surgery for early vulvar cancer 2011 · Cochrane Headline outcomes only
RR 3.7 [0.87, 15.8]
1 study · 52 participants
Low

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Overall Survivalclinical observation · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.02 [0.97, 1.06]
2 studies · 1998 participants
High

Topotecon vs Topotecon+thalidomide

Overall response · patients with EOC

Topotecon may leads to lower overall response compared with topotecon+thalidomide (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
RR 0.47 [0.23, 0.99]
1 study · 75 participants
Low

Topotecan vs treosulfan

Overall survival · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
High

Topotecan vs treosulfan

Progression‐free survival · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
High

Topotecan vs treosulfan

Response to treatment · patients with EOC

Topotecan probably leads to higher response to treatment compared with treosulfan (moderate certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
RR 1.76 [1.06, 2.94]
1 study · 274 participants
Moderate

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Progression‐free survival · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel may leads to higher progress free survival compared with carboplatin+Paclitaxel (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.03 [1.03, 1.03]
2 studies · 1998 participants
Low

Topotecon vs PLD alone

Survival Hazard Ratio (platium‐sensitive) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Topotecon vs PLD alone

Survival Hazard Ratio (Platium‐resistant) · patients with EOC

Topotecon showed no clear difference in survival Hazard Ratio (Platium‐resistant) compared with PLD (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
RR 0.69 [0.35, 1.38]
1 study · 255 participants
Low

Topotecon vs PLD alone

Progression free survival (platium‐sensitive) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Topotecon vs PLD alone

Progression free survival (platium‐resistant) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Topotecon vs 175 mg/m2 paclitaxel

SurvivalScale from: 1 to 226.3. · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 226 participants
High

Topotecon vs 175 mg/m2 paclitaxel

Time to progressionScale from: 1 to 137.3. · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 226 participants
High

Topotecon vs Topotecon+thalidomide

Progression‐free survival · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
High